FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products

August 15, 2022

Icons for different filename types to represent electronic submissions.

This technical specifications document is to assist interested parties in electronically submitting individual case safety reports (ICSRs) (and ICSR attachments) to the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) in the Food and Drug Administration (FDA or Agency). This document describes FDA’s technical approach for submitting ICSRs, for incorporating its regionally controlled terminology,1 and for adding FDA Adverse Event Reporting System (FAERS) regional data elements that are not addressed in the International Conference on Harmonisation’s (ICH) E2B (R3) Implementation Guideline (IG) for the following FDA-regulated products:

  • Drug products marketed for human use with approved new drug applications (NDAs) and abbreviated new drug applications (ANDAs)
  • Prescription drug products marketed for human use without an approved application
  • Nonprescription (over-the-counter human drug products marketed without an approved application)
  • Biological products marketed for human use with approved biologic license applications (BLAs).

Download the Final Guidance Document

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.


Person using a stylus to work on a tablet.

May 4, 2022

Implementation of ICH E2B(R3)

April 2022 Guidance Document E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide...

April 19, 2016

Minimizing Medication Errors Related to Product Design, Part One: FDA’s Recommendations for Conducting Proactive Risk Assessments

On September 27, 2007, the Prescription Drug User Fee Act (PDUFA IV) reauthorization and expansion was signed into law, significantly strengthening FDA’s drug safety program. As part of the...

August 4, 2016

FDA Generic Drug User Fee Rates: Fiscal Year 2017

FDA has announced its 2017 user fee rates related to the Generic Drug User Fee Program, which includes: Abbreviated new drug applications (ANDAs) Prior approval supplements (PASs) to an approved ANDA...